Orient Europharma Co., Ltd. AI Stock Analysis
Orient Europharma Co., Ltd. (4120) AI Stock Analysis
Orient Europharma Co., Ltd.
(TPEx:4120)
The overall score of 40 reflects a financially distressed company with deeply bearish market momentum. The most significant factor is the company's inability to generate profits or cash from operations, despite stable revenue and decent gross margins, which raises concerns about its cost structure and long-term viability. This fundamental weakness is mirrored in the technicals, with the stock in a clear downtrend and showing no signs of reversal. The high dividend yield is a red flag rather than an attraction, as it is likely unsustainable given the ongoing cash burn. The improved balance sheet is the only relative bright spot but is insufficient to offset the severe operational and market challenges.
Orient Europharma Co., Ltd. (4120) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.67B
- Dividend Yield
- 9.39%
- Average Volume (3M)
- 21.60K
- Price to Earnings (P/E)
- -6.8
- Beta (1Y)
- 0.15
- Revenue Growth
- 4.35%
- EPS Growth
- -17.92%
- Country
- TW
- Employees
- 339
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Orient Europharma Co., Ltd. Business Overview & Revenue Model
Company Description
Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, s...
Orient Europharma Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak. While gross margins are healthy (43-47%) and the balance sheet has improved via deleveraging (debt-to-equity down to 0.52), the company is deeply unprofitable. The TTM net loss of NT$567 million, negative EBIT margins, and a return on equity of -9.0% indicate severe operational inefficiencies. Critically, operating and free cash flows are persistently negative, signaling a cash burn that threatens financial stability.
Income Statement
38NegativeBalance Sheet
55NeutralCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.65B | 4.60B | 4.39B | 4.59B | 4.73B | 4.77B |
| Gross Profit | 2.17B | 2.10B | 2.07B | 2.15B | 2.03B | 2.15B |
| EBITDA | -145.21M | -121.76M | 183.90M | 596.88M | -34.15M | 133.32M |
| Net Income | -538.56M | -567.39M | -283.93M | 143.94M | -310.80M | 120.17M |
Balance Sheet | ||||||
| Total Assets | 11.75B | 12.21B | 11.57B | 10.81B | 10.43B | 9.40B |
| Cash, Cash Equivalents and Short-Term Investments | 1.67B | 2.12B | 1.89B | 2.14B | 1.95B | 2.06B |
| Total Debt | 3.53B | 3.27B | 4.23B | 4.84B | 5.03B | 4.23B |
| Total Liabilities | 5.41B | 4.85B | 5.75B | 6.65B | 6.99B | 5.95B |
| Stockholders Equity | 5.23B | 6.29B | 5.16B | 3.51B | 2.93B | 2.94B |
Cash Flow | ||||||
| Free Cash Flow | -825.61M | -472.30M | -221.31M | 20.28M | -859.84M | -1.49B |
| Operating Cash Flow | -598.50M | -298.63M | -121.11M | 120.98M | -218.75M | 77.65M |
| Investing Cash Flow | 120.45M | 1.62B | 465.20M | 62.11M | -611.56M | -1.50B |
| Financing Cash Flow | -105.50M | -1.05B | -760.92M | -209.71M | 428.31M | 1.36B |
Orient Europharma Co., Ltd. Peers Comparison
Overall Rating
TW:177782Outperform
TW:178650Neutral
TW:412040Underperform
TW:687537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | TWD 3.33B | 9.02 | ― | 5.36% | 1.01% | 41.25% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | TWD 3.52B | 24.28 | ― | 4.05% | -2.25% | -15.57% | |
| 40Underperform | TWD 3.70B | -6.76 | ― | 9.39% | 4.35% | -17.92% | |
| 37Underperform | TWD 3.15B | -8.94 | ― | ― | -60.37% | -77.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4120 | Orient Europharma Co., Ltd. | 42.60 | 1.40 | 3.39% | |
| TW:1777 | SYN-TECH Chemical & Pharmaceutical Co. Ltd. | 74.60 | 2.07 | 2.85% | |
| TW:1786 | SciVision Biotech Inc. | 47.10 | -26.70 | -36.18% | |
| TW:6634 | Sinew Pharma, Inc. | 57.70 | 18.70 | 47.95% | |
| TW:6875 | Pharmosa Biopharm Inc. | 24.40 | -22.15 | -47.58% | |
| TW:6885 | BRIM Biotechnology, Inc. | 27.75 | -0.95 | -3.31% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
